| Autor: |
Ikuto, Tsukiyama, Masahiko, Ando, Sumiyo, Tsukiyama, Masayuki, Takeuchi, Masayuki, Ejiri, Yusuke, Kurose, Hiroko, Saito, Ichiro, Arakawa, Tadao, Inoue, Etsuro, Yamaguchi, Akihito, Kubo |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 27(10) |
| ISSN: |
1433-7339 |
| Popis: |
Neurokinin-1 receptor antagonist (NKA decision-analytic model was developed according to the necessity of aprepitant and CINV responses in both acute and delayed phases of chemotherapy. Probabilities of health states and medical costs were derived from the results of the abovementioned trial.In patients who received HEC and needed aprepitant, the incremental cost-effectiveness ratio (ICER) with aprepitant, relative to the regimen with no aprepitant, was 7912 US dollars (USD) per quality-adjusted life year (QALY) gained, which was far below the commonly accepted threshold of 50,000 USD/QALY. The ICER was 27,457 USD/QALY in patients who received MEC and needed aprepitant. In contrast, in patients who received HEC or MEC but did not need aprepitant, the ICER was 175,959 or 478,844 USD/QALY, respectively.Regardless of whether a patient received HEC or MEC, aprepitant use was highly cost-effective for patients who truly needed it. These results warrant further research to predict the necessity of NK |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink